Hearing Amylin Considering Sale -Reuters
Amylin (NASDAQ: AMLN) is considering a sale of the company, according to sources cited by Reuters. Amylin is attempting to fight off a law suit by investor Carl Icahn. The company recently rejected a $3.5 billion takeover offer from Bristol-Myers Squibb (NYSE: BMY).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.